2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.33 (Poster) Comparison of Baseline Risk of Developing and Dying from Lung Cancer in Screen Eligible General Versus Trial Populations

PP01.33 (Poster) Comparison of Baseline Risk of Developing and Dying from Lung Cancer in Screen Eligible General Versus Trial Populations

Back to course

Pdf Summary

A study compared the risk of developing and dying from lung cancer among individuals who underwent lung cancer screening (LCS) in a real-world setting (North Carolina Lung Screening Registry - NCLSR), participants in the National Lung Screening Trial (NLST), and two general populations of ever-smokers and LCS-eligible individuals. The results showed that the NCLSR population had a similar distribution of smoking status as the NLST, but they were older and more likely to have comorbid conditions such as chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, diabetes, hypertension, and stroke. This resulted in a higher 5-year risk of lung cancer death in the NCLSR population compared to NLST participants.<br /><br />The study also compared the probability of developing lung cancer within 5 years if not screened (LCRAT) and the probability of dying from lung cancer within 5 years if not screened (LCDRAT) in the NCLSR population to the two general US populations. The NCLSR population had a higher LCRAT and LCDRAT compared to ever-smoking individuals and LCS-eligible individuals from the general populations. These findings suggest that the NCLSR population has a higher risk of developing and dying from lung cancer compared to the general populations.<br /><br />The study highlights the importance of monitoring the screening performance and outcomes in the general population as these individuals are older and have more comorbid illnesses, which increase the risk of both lung cancer and competing mortality risks. Understanding the baseline risk of developing and dying from lung cancer among different populations is crucial in determining the net benefit of LCS and making informed screening recommendations.<br /><br />The research was supported by the National Cancer Institute and the National Center for Advancing Translational Sciences. The North Carolina Lung Screening Registry provides valuable data for studying lung cancer risk and screening outcomes, and more information about the registry can be found on their website.

Asset Subtitle

MP Rivera

Keywords

lung cancer screening

North Carolina Lung Screening Registry

National Lung Screening Trial

smoking status

comorbid conditions

5-year risk

lung cancer death

probability of developing lung cancer

probability of dying from lung cancer

baseline risk